Targeting Protein Serine/Threonine Phosphatases for Drug Development
AUTOR(ES)
McConnell, Jamie L.
FONTE
American Society for Pharmacology and Experimental Therapeutics
RESUMO
With the recent clinical success of drugs targeting protein kinase activity, drug discovery efforts are focusing on the role of reversible protein phosphorylation in disease states. The activity of protein phosphatases, enzymes that oppose protein kinases, can also be manipulated to alter cellular signaling for therapeutic benefits. In this review, we present protein serine/threonine phosphatases as viable therapeutic targets, discussing past successes, current challenges, and future strategies for modulating phosphatase activity.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2684880Documentos Relacionados
- Effects of Inhibitors of Protein Serine/Threonine Phosphatases on Pollination in Brassica.
- Inhibitors of serine/threonine phosphoprotein phosphatases alter circadian properties in Gonyaulax polyedra.
- Characterization of a Hank’s Type Serine/Threonine Kinase and Serine/Threonine Phosphoprotein Phosphatase in Pseudomonas aeruginosa
- Human cytomegalovirus carries serine/threonine protein phosphatases PP1 and a host-cell derived PP2A.
- PPX, a novel protein serine/threonine phosphatase localized to centrosomes.
